Di Virgilio Francesco, Vuerich Marta
Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, University of Ferrara Italy.
Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, University of Ferrara Italy.
Auton Neurosci. 2015 Sep;191:117-23. doi: 10.1016/j.autneu.2015.04.011. Epub 2015 Apr 30.
Extracellular ATP and its metabolite adenosine are increasingly recognized as key mediators of the immune response. Depending on the concentration, ATP may act as an immunostimulant or an immunodepressant, while adenosine is generally acknowledged to be a potent immunosupressor molecule. Signals delivered by extracellular ATP and adenosine are detected and transduced by P2 and P1 receptors, respectively. Virtually all immune cells express P2 and P1 receptors, thus purinergic signaling affects all aspects of immunity and inflammation. This realization has prompted a burst of novel investigations aimed at the design and synthesis of P2- or P1-targeted drugs for the treatment of chronic inflammatory diseases and cancer. In this review we will summarize the most recent developments in this field.
细胞外ATP及其代谢产物腺苷日益被认为是免疫反应的关键介质。根据浓度不同,ATP可能充当免疫刺激剂或免疫抑制剂,而腺苷通常被认为是一种强大的免疫抑制分子。细胞外ATP和腺苷传递的信号分别由P2和P1受体检测和转导。几乎所有免疫细胞都表达P2和P1受体,因此嘌呤能信号传导影响免疫和炎症的各个方面。这一认识促使人们开展了一系列新的研究,旨在设计和合成针对P2或P1的药物,用于治疗慢性炎症性疾病和癌症。在本综述中,我们将总结该领域的最新进展。